Paul D, Flouret G, Tomita J T, Ranney K, Schenck J, Anderson B
Cancer Res. 1981 Jun;41(6):2315-21.
A tetracosapeptide (peptide-24) corresponding to the amino-terminal sequence of the carcinoembryonic antigen (CEA) was synthesized and characterized. Antisera were produced to the peptide-24, and a radioimmunoassay was developed utilizing peptide-24 with a tyrosine residue on the amino-terminal end (Tyr-peptide-24). Inhibitions of anti-peptide-24-125I-Tyr-peptide-24 complex formation were done with several preparations of CEA and the normal cross-reacting antigen. The extent of cross-reactivities was low, one CEA preparation requiring a 250-fold molar quantity greater than peptide-24 to obtain the same degree of inhibition. Attempts to degrade the CEAs and normal cross-reacting antigens in order to possibly expose the amino-terminal ends for reactivity with antibody did not result in any great increase in inhibitory capacity. It was concluded that either the conformations of the antigenic determinant(s) of the peptide-24 and of the amino-terminal end of CEA were sufficiently different to result in little cross-reacting antigen are blocked for reactivity with antibody by other portions of the molecule.
合成并表征了一种与癌胚抗原(CEA)氨基末端序列相对应的二十四肽(肽 - 24)。制备了针对肽 - 24的抗血清,并利用氨基末端带有酪氨酸残基的肽 - 24(Tyr - 肽 - 24)建立了放射免疫测定法。用几种癌胚抗原制剂和正常交叉反应抗原进行了抗肽 - 24 - 125I - Tyr - 肽 - 24复合物形成的抑制实验。交叉反应程度较低,一种癌胚抗原制剂需要比肽 - 24大250倍的摩尔量才能获得相同程度的抑制。试图降解癌胚抗原和正常交叉反应抗原以可能暴露氨基末端与抗体反应,但并未导致抑制能力有任何显著增加。得出的结论是,要么肽 - 24的抗原决定簇构象与癌胚抗原氨基末端的构象差异足够大,导致交叉反应抗原很少,要么癌胚抗原分子的其他部分阻碍了氨基末端与抗体的反应性。